Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 1;197(11):1483-1486.
doi: 10.1164/rccm.201710-2046LE.

Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement

Sonya L Heltshe  1   2 , Steven M Rowe  3 , Michelle Skalland  2 , Arthur Baines  2 , Manu Jain  4 ; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network
Affiliations

Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement

Sonya L Heltshe et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
FEV1 percentage predicted (PP) rate of decline 2 years pre- and postivacaftor by 1-month FEV1 response categories (responders had >0 PP change at 1 month postivacaftor [gray solid line]; nonresponders had ≤0 PP change [black dashed line]). Means and 95% confidence intervals. GLI = Global Lung Function Initiative equations (6).
See this image and copyright information in PMC

References

    1. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–1672. - PMC - PubMed
    1. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al. GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190:175–184. - PMC - PubMed
    1. De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13:674–680. - PubMed
    1. Sawicki GS, McKone EF, Pasta DJ, Millar SJ, Wagener JS, Johnson CA, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015;192:836–842. - PubMed
    1. Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, et al. The Cystic Fibrosis Foundation Patient Registry. design and methods of a national observational disease registry. Ann Am Thorac Soc. 2016;13:1173–1179. - PubMed

Publication types